Longevity Science FAQ

The translation to humans went through a turbulent decade. In 2014, Wyss-Coray co-founded Alkahest, a biotech aimed at developing plasma-derived rejuvenation therapies. Alkahest began clinical trials of young plasma fractions in Alzheimer's disease. The PLASMA trial (Plasma for Alzheimer Symptom Amelioration), published in 2019 in JAMA Neurology by Sha et al., tested young donor plasma infusions in mild-to-moderate Alzheimer's patients. The results were null on primary cognitive endpoints, though the small sample size and short duration limited interpretation. Alkahest pivoted toward specific plasma fractions rather than whole plasma, and was eventually acquired by Grifols, a Spanish plasma products company, which has continued developing fractionated products for neurological indications.

Mandsager et al. 2018 (JAMA Network Open) — Cleveland Clinic. The single most influential modern study on VO2 max and mortality. Over 122,000 patients undergoing treadmill exercise testing were followed for a median of 8.4 years. Cardiorespiratory fitness was inversely associated with mortality with no observed upper limit of benefit. The adjusted hazard ratio comparing elite fitness (top 2.5%) to low fitness (bottom 25%) was around 0.20 — an 80% reduction in all-cause mortality risk. For comparison, the hazard ratio associated with being a current smoker versus never-smoker was about 1.41. In other words, low fitness was a stronger mortality signal than smoking. Researchers emphasized that unlike smoking, fitness is modifiable across the entire spectrum.

The blue zones literature has practical relevance for gene editing and peptide longevity research because it identifies candidate pathways from human population observation. The Sardinian M26 variant, the Ashkenazi CETP and APOE variants, and the FOXO3A variants associated with Okinawan longevity all point to specific biological mechanisms that could be targeted therapeutically. CETP inhibitors have already been developed as cardiovascular drugs (anacetrapib, obicetrapib), directly inspired by the centenarian genetics literature. FOXO3A signaling is a conserved longevity pathway engaged by rapamycin, caloric restriction, and insulin signaling — pointing to editing or pharmacological approaches that mimic the protective allele.

For years after its discovery, irisin's receptor was unknown, and critics argued that any hormone without a receptor should be treated with skepticism. In 2018, Kim et al. published in Cell the identification of αV/β5 integrins as the irisin receptor on osteocytes and adipocytes. Integrin binding activates focal adhesion kinase (FAK), ERK signaling, and downstream transcriptional programs that drive browning in fat and remodeling in bone. This integrin-based receptor mechanism is unusual for a hormone — most endocrine factors use classical seven-transmembrane receptors or receptor tyrosine kinases — and explains some of the early confusion about irisin's signaling.

FGF21 is a 181-amino-acid peptide hormone secreted primarily by the liver, though pancreatic, muscle, and adipose tissue also contribute during specific physiological states. Unlike classical fibroblast growth factors, which act locally as paracrine signals, FGF21 is an endocrine FGF — it circulates in the blood and acts on distant tissues. Its receptor complex requires both an FGF receptor (FGFR1c, FGFR2c, or FGFR3c) and the obligate coreceptor β-Klotho, which is expressed predominantly in adipose tissue, brain, and pancreas. This receptor specificity explains why FGF21 affects metabolism without triggering the proliferative effects of other FGFs.

A reasonable summary of current blue zones longevity science looks something like this. The centenarian density claims are weaker than originally presented and contaminated by record quality issues. The lifestyle observations — plant-forward eating, moderate daily movement, social connection, purpose — are supported by independent prospective cohort studies and are real determinants of longevity, even if they don't specifically add 10 years. The Sardinian and Okinawan dietary patterns have independent experimental support. The Loma Linda Adventist Health Study is the gold standard and stands regardless of the broader critique.

The 2009 Harrison et al. ITP paper showed median lifespan extension of 9% in males and 14% in females when rapamycin was started at 20 months. Follow-up ITP papers (Miller et al. 2011, 2014; Strong et al. 2020) replicated the effect across three independent labs — the gold standard for preclinical reproducibility — and demonstrated a dose-response relationship, with higher doses producing larger lifespan gains (up to ~23% median extension in females at the highest dose tested). Rapamycin is, as of 2026, the only pharmacological intervention to produce robust, reproducible, late-life lifespan extension in mammals in the ITP.

The plasma dilution finding has motivated a new generation of clinical approaches. Irina Conboy co-founded Immunis, a company developing immune-modulating plasma-derived therapeutics based on the dilution insight. Other groups have pursued therapeutic plasma exchange (TPE), a procedure already FDA-approved for autoimmune conditions like myasthenia gravis and TTP, as a potential longevity intervention. Small studies have tested TPE in Alzheimer's disease, with the AMBAR trial reporting modest cognitive benefits in a 2020 Alzheimer's & Dementia publication using albumin replacement during plasma exchange.

The off-label rapamycin community in 2026 is anchored by a handful of clinician-researchers. Matt Kaeberlein (formerly University of Washington, now leading Optispan) is probably the most cited voice. Kaeberlein publicly discontinued his own rapamycin use after developing suspected side effects, and has been careful to frame rapamycin as "the most promising geroscience drug we have, but the human evidence is still thin." Alan Green, a New York physician, has been prescribing rapamycin off-label to thousands of patients since 2017 and publishes case-series observations (not RCT-quality data) on the protocol.

Nicotinamide adenine dinucleotide (NAD+) is one of the most fundamental molecules in biology, discovered in 1906 by Harden and Young and later recognized as a critical coenzyme by Otto Warburg. It shuttles electrons in cellular respiration, serves as a substrate for sirtuins (the longevity-associated deacetylase family), and is consumed by PARPs during DNA repair and by CD38 during inflammation. Tissue NAD+ levels decline meaningfully with age — a finding reported across multiple model organisms and human tissues — which is the central motivator for "NAD+ restoration" as an aging intervention.

The limitations of GDF11 science are profound and worth stating clearly. Almost every published measurement of circulating GDF11 is suspect due to antibody cross-reactivity with myostatin. Effects reported in aged mice have not been consistently reproduced across laboratories. Dose-response relationships are unclear, with some groups reporting benefits at nanogram doses and others reporting toxicity at the same range. The mechanism of action in aged tissue is not well-defined — SMAD2/3 signaling is broadly growth-inhibitory, which is difficult to reconcile with a pro-regenerative effect.

The original 2012 Boström et al. Nature paper established the muscle-to-fat signaling axis. The following year, Erickson (2013) in a highly critical Adipocyte commentary raised concerns about the commercial ELISA kits used to measure irisin, arguing that they cross-reacted with other proteins and that human irisin might not exist at all. This critique was taken seriously — several groups reported failing to detect irisin in human plasma by Western blot, and a 2015 Nature paper questioned whether the human FNDC5 gene produces a functional protein given a non-canonical start codon.

The 2005 paper and its follow-ups established several key findings. First, aging tissue stem cells retain intrinsic regenerative capacity — they are not simply "worn out" — but are held back by extrinsic systemic signals. Exposing them to a young circulatory environment reactivates their function within days. Second, young tissue stem cells are damaged by exposure to old blood, suggesting that aged plasma contains pro-aging factors. Third, specific signaling pathways mediate these effects, including Notch (activated by young blood) and TGF-β family signaling (elevated with age).

Kumar et al. 2021 (Clinical & Translational Medicine). This pilot open-label study gave eight older adults (ages 70-80) GlyNAC for 24 weeks at doses of 100 mg/kg/day glycine and 100 mg/kg/day NAC. Outcomes included GSH, oxidative stress markers, mitochondrial function, insulin resistance, inflammation, endothelial function, genotoxicity, muscle strength, gait speed, exercise capacity, and cognition. The results were striking across nearly all domains. But with eight participants and no control group, the study was hypothesis-generating rather than confirmatory.

Rapamycin (sirolimus) is a macrolide compound originally isolated in 1972 by Suren Sehgal and colleagues from Streptomyces hygroscopicus, a soil bacterium collected on Rapa Nui (Easter Island) — the source of the drug's name. Sehgal initially characterized it as an antifungal. It turned out to be far more interesting than that. By the 1990s, rapamycin had been approved by the FDA (1999) as an immunosuppressant to prevent kidney transplant rejection, and a decade later was approved in drug-eluting coronary stents and for the rare disease lymphangioleiomyomatosis.

Metformin is a biguanide, chemically derived from guanidine compounds found in the French lilac (Galega officinalis), a plant used in medieval Europe for urinary frequency — one of the classic symptoms of undiagnosed diabetes. The modern drug was synthesized in the 1920s, clinically introduced in France by Jean Sterne in 1957 under the name Glucophage ("glucose eater"), and finally approved by the US FDA in 1994 after decades of use in Europe. It is today the most prescribed oral diabetes drug in the world and sits on the WHO Essential Medicines list.

Gerontologist Valter Longo, director of the Longevity Institute at the University of Southern California, has spent over two decades studying the relationship between fasting, nutrient sensing, and aging. His work bridges basic research on fasting biology and clinical application through what he calls the fasting-mimicking diet (FMD) — a carefully designed five-day regimen of low-calorie, low-protein, plant-based foods that provides enough nutrition to avoid the challenges of a water fast while still triggering fasting-related cellular responses.

An epigenetic clock is a mathematical model — usually a weighted linear combination of DNA methylation levels at specific CpG sites in the genome — that produces an estimate of "biological age" from a blood, saliva, or tissue sample. The inputs are percent-methylation values at hundreds of CpG sites measured on DNA methylation arrays (originally the Illumina 27K, then 450K, then EPIC 850K, and now EPIC v2). The output is a single number in years, intended to represent how old your body looks methylation-wise, independent of calendar age.

Klotho is a transmembrane protein that also exists as a cleaved, circulating soluble hormone. It was discovered by Makoto Kuro-o's group and reported in Nature in 1997. The paper described mice with a transposon insertion that disrupted the Klotho gene; these mice developed premature aging phenotypes — infertility, atherosclerosis, osteoporosis, thymic atrophy, pulmonary emphysema — and had a median lifespan of about 8 to 9 weeks. Overexpression of Klotho, in a 2005 Science follow-up, extended mouse lifespan by roughly 20 to 30 percent.

Then there is Saul Justin Newman's work. Newman, a demographer at University College London, published a preprint in 2019 and follow-up work that was widely discussed in 2024, arguing that many regions with high reported centenarian density share one striking feature: poor vital records. His analysis found that across multiple countries, the regions with the highest reported supercentenarian density were also regions with the worst birth certification, the highest historical pension fraud, or the most incomplete record-keeping.

Proteostasis — short for protein homeostasis — refers to the integrated network that controls the synthesis, folding, trafficking, and degradation of every protein in a cell. The López-Otín et al. 2013 Cell hallmarks paper defined "loss of proteostasis" as the age-related deterioration of this network, leading to accumulation of damaged or misfolded proteins. The 2023 update kept it as a primary hallmark and added "disabled macroautophagy" as a closely related but distinct hallmark, recognizing autophagy's central role.

The off-label metformin-for-longevity crowd is meaningfully smaller and more cautious than it was five years ago. Peter Attia, who previously discussed metformin favorably, publicly revised his position in recent years, citing the exercise-blunting data and downgrading metformin's priority in his stack. Nir Barzilai remains the most prominent advocate, framing metformin as a proof-of-concept for the geroscience hypothesis — the idea that targeting aging biology can delay multiple age-related diseases at once.

FGF21 is induced by metabolic stress. Fasting raises FGF21 through PPARα activation in the liver. Protein restriction — particularly restriction of methionine or branched-chain amino acids — raises FGF21 through the amino acid sensing GCN2/eIF2α/ATF4 pathway, which detects uncharged tRNAs and activates the integrated stress response. Cold exposure induces FGF21 in brown adipose tissue through β-adrenergic signaling. Alcohol, mitochondrial dysfunction, and endoplasmic reticulum stress all raise FGF21 as well.

DNA methylation — the addition of methyl groups to cytosine bases, primarily at CpG dinucleotides — is the best-studied epigenetic modification in the context of aging. As cells age, they undergo predictable changes: some regions gain methylation while others lose it. Certain CpG islands near gene promoters become hypermethylated, silencing genes that should be active. Meanwhile, repetitive DNA elements lose methylation, potentially reactivating transposable elements and contributing to genomic instability.

VO2 max is the maximum rate at which your body can consume oxygen during intense exercise, measured in milliliters of oxygen per kilogram of body weight per minute (mL/kg/min). It integrates the performance of every link in the oxygen delivery chain: lung gas exchange, cardiac output, hemoglobin-bound oxygen transport, capillary density, mitochondrial content and efficiency in working muscle, and the ability to buffer metabolic byproducts. If any of these systems is weak, your VO2 max is weak.

In 2011, researchers at the Mayo Clinic made a landmark discovery. Using a genetic trick in mice engineered to allow selective elimination of senescent cells (the INK-ATTAC model), they showed that clearing p16-positive senescent cells delayed age-related pathology in multiple organs. The treated mice had better kidney function, healthier hearts, and longer healthspans. A follow-up study in 2016 demonstrated that senescent cell clearance extended median lifespan by 25% in naturally aged mice.

The term "blue zone" was coined by Belgian demographer Michel Poulain and Italian medical statistician Gianni Pes, who in 2004 identified a cluster of remarkable longevity in the Nuoro province of Sardinia. Poulain drew blue circles on maps to mark the regions, and the name stuck. National Geographic writer Dan Buettner popularized the concept in a 2005 cover story and a 2008 book, The Blue Zones, identifying five regions based on reported centenarian density and commonalities in lifestyle.

When cells experience severe stress or DNA damage, they can enter a state called senescence — they stop dividing permanently but do not die. In small numbers, senescent cells serve useful purposes like wound healing and tumor suppression. But with age, they accumulate in tissues and secrete a toxic cocktail of inflammatory molecules, growth factors, and enzymes known as the senescence-associated secretory phenotype (SASP). This poisons neighboring cells and drives chronic inflammation.

Several well-funded companies are racing to translate epigenetic reprogramming into human therapies. Altos Labs, backed by more than $3 billion in funding, has recruited top researchers including Yamanaka himself to develop reprogramming-based medicines. Retro Biosciences is focused on partial reprogramming and other longevity interventions. Turn Biotechnologies is developing mRNA-based delivery of reprogramming factors, which offers a potentially safer alternative to viral vectors.

For decades, aging research focused on DNA mutations as the primary driver of biological decline. But a compelling body of evidence now points to a different culprit: the epigenome. While your DNA sequence — your genetic code — remains largely stable throughout life, the chemical modifications that sit on top of that code change dramatically as you age. These modifications, collectively called the epigenome, control which genes are active and which are silent in any given cell.

Irisin is a 112-amino-acid peptide generated by proteolytic cleavage of the extracellular domain of FNDC5 (Fibronectin type III Domain-Containing protein 5), a type I transmembrane protein expressed primarily in skeletal muscle, but also in heart, brain, and adipose tissue. During exercise, the transcriptional coactivator PGC-1α drives FNDC5 expression in muscle. The FNDC5 protein is then cleaved, releasing irisin into circulation where it acts on distant tissues as a hormone.

Bryan Johnson is not a scientist. He is an entrepreneur who made his fortune in financial technology. In 2007, he founded Braintree, a payment processing company that eventually acquired Venmo. In 2013, PayPal purchased Braintree for $800 million. Johnson used a portion of that wealth to fund OS Fund, a venture capital firm investing in technologies that "reprogram the world's most complex systems," and later Kernel, a neuroscience company developing brain-computer interfaces.

Perhaps the most important criticism of Blueprint is not scientific but practical: almost none of it is replicable for ordinary people. Johnson's protocol requires a personal medical team, access to experimental procedures, and a budget that exceeds most families' lifetime earnings. The implicit message -- that defeating aging requires extraordinary wealth -- could discourage people from making the simple, evidence-based changes that would actually improve their healthspan.

In the López-Otín et al. 2013 Cell framework, mitochondrial dysfunction is defined as the age-related decline in the efficiency of the electron transport chain together with increased electron leakage, reduced ATP generation, and accumulating damage to mitochondrial DNA (mtDNA). The 2023 update preserved it as one of the twelve hallmarks, recognizing that it both causes and amplifies others — particularly cellular senescence, chronic inflammation, and stem cell exhaustion.

Urolithin A (UA) is a small molecule that most people cannot make directly from the foods they eat. It is a gut microbiome metabolite produced when certain bacteria transform dietary ellagitannins — polyphenols abundant in pomegranates, walnuts, strawberries, raspberries, and some teas. The precursor chain goes: ellagitannins → ellagic acid → (gut bacteria) → urolithins A, B, C, D, and others. Urolithin A is the one with the most interesting biological activity.

A decade ago, working on aging was considered career suicide in mainstream biology. Today, longevity biotech is one of the hottest sectors in life sciences, attracting billions in investment from tech billionaires, pharmaceutical giants, and sovereign wealth funds. The field has shifted from fringe to frontier science, and a new generation of companies is translating decades of academic research into therapies designed to slow, halt, or reverse human aging.

Mitochondria are the power plants of cells, converting nutrients into the energy currency ATP. Aged mitochondria produce energy less efficiently, generate more damaging reactive oxygen species, and accumulate mutations in their own small genome. Dysfunctional mitochondria also release signals that trigger inflammation and cell death. Mitochondrial decline is thought to be a major driver of the fatigue and reduced physical capacity that comes with aging.

Parabiosis is a surgical procedure in which two living animals — usually mice — are joined so that they share a common circulatory system through natural capillary anastomoses formed at the suture site. The technique was pioneered in the 1860s by the French physiologist Paul Bert, and was used sporadically through the twentieth century to study hormonal signaling, obesity (McCay, 1956), and the relationship between systemic factors and tissue biology.

For decades, scientists assumed that aging was primarily driven by the accumulation of genetic mutations. Damaged DNA, the thinking went, gradually destroyed cellular function until organs failed. But a revolutionary insight has upended that model: much of aging appears to be an epigenetic phenomenon. Your DNA sequence stays largely intact as you age, but the chemical marks that control how genes are read — the epigenome — become disordered over time.

Denham Harman first proposed the free radical theory of aging in 1956, then refined it into the mitochondrial free radical theory in 1972. The original idea — that ROS damages everything and that's why we age — turned out to be too simple. Antioxidant supplementation trials largely failed, and some long-lived species actually have higher ROS production. But the underlying organelle Harman pointed at was the right culprit, just for different reasons.

The breakthrough came from the idea of partial reprogramming — exposing cells to Yamanaka factors for a limited time, just enough to rejuvenate them without fully reverting them to a stem cell state. In 2016, Juan Carlos Izpisua Belmonte's lab at the Salk Institute demonstrated this concept in progeria mice (which age prematurely). Cyclic expression of OSKM factors extended their lifespan by 30% and reversed signs of aging in multiple tissues.

Intermittent fasting encompasses several approaches — time-restricted eating (typically 16:8, where eating is confined to an 8-hour window), alternate-day fasting, and the 5:2 method (eating normally five days per week, restricting to 500-600 calories on two non-consecutive days). The hypothesis is that periodic fasting triggers some of the same cellular stress responses as sustained caloric restriction without requiring permanent hunger.

The epigenome — chemical modifications that control which genes are turned on or off — becomes increasingly disordered with age. DNA methylation patterns drift, histone modifications change, and chromatin structure loosens. The result is that genes meant to be silent become active and vice versa, disrupting normal cellular function. This hallmark is particularly exciting because epigenetic changes may be reversible through reprogramming.

Cells have signaling pathways that detect nutrient availability and adjust metabolism accordingly. The key players include insulin/IGF-1 signaling, mTOR, AMPK, and sirtuins. With age, these pathways become dysregulated — cells behave as if nutrients are always abundant, promoting growth and suppressing repair. This is why caloric restriction and fasting extend lifespan in many organisms: they restore appropriate nutrient sensing.

When a polypeptide leaves the ribosome, it is vulnerable. About 30% of newly synthesized proteins fail to fold correctly on the first try. HSP70 and the chaperonin TRiC catch them and either help them fold or hand them off to the ubiquitin ligase machinery for degradation. HSP90 manages a special clientele of signaling kinases and steroid receptors. Small heat shock proteins act as holdases, preventing aggregation under stress.

Alpha-ketoglutarate (AKG, also called 2-oxoglutarate) is a five-carbon dicarboxylic acid that is one of the central intermediates of the tricarboxylic acid (TCA, or Krebs) cycle — the mitochondrial engine that converts acetyl-CoA from carbohydrate, fat, and protein into the reducing equivalents that power ATP synthesis. AKG sits between isocitrate and succinyl-CoA in the cycle and is produced by isocitrate dehydrogenase (IDH).

Cells rely on a network of quality control mechanisms — chaperones, the proteasome, and autophagy — to keep their proteins properly folded and functional. With age, this proteostasis network breaks down. Misfolded and aggregated proteins accumulate, contributing to diseases like Alzheimer's (amyloid plaques) and Parkinson's (alpha-synuclein aggregates). The cellular machinery simply cannot keep up with the maintenance burden.

Taurine is a conditionally essential amino sulfonic acid — not quite a standard amino acid (it lacks a carboxyl group), not quite a vitamin. It is abundant in meat, fish, and shellfish, and is synthesized endogenously from cysteine and methionine by most mammals. It is one of the most abundant free amino acid-like molecules in heart, skeletal muscle, brain, and retina. Historically, taurine has been studied for its roles in:

GDF11, or Growth Differentiation Factor 11, is a member of the TGF-β superfamily of signaling proteins. It's structurally almost identical to myostatin (GDF8), the famous muscle-limiting factor, sharing roughly 90 percent amino acid sequence identity in its mature domain. Both are secreted as inactive precursors, cleaved by proteases, and bind to activin type II receptors (ActRIIA/B) to trigger SMAD2/3 signaling cascades.

Epigenetic reprogramming represents perhaps the most audacious bet in modern biology — the idea that aging is not an irreversible process but a software problem that can be debugged. The scientific foundations are solid: partial reprogramming demonstrably reverses molecular markers of aging in cells and in mice. The investment is unprecedented. And the potential market — essentially every human being — is limitless.

In 1961, Leonard Hayflick made a discovery that challenged the prevailing belief that normal cells could divide indefinitely. Working with human fibroblasts (connective tissue cells) in culture, he observed that they divided vigorously for a while — about 50 to 70 divisions — and then stopped. They did not die immediately, but they entered a state of permanent growth arrest that we now call cellular senescence.

In 2006, Shinya Yamanaka made a discovery that earned him the Nobel Prize. He showed that just four transcription factors — OCT4, SOX2, KLF4, and c-MYC (collectively known as OSKM) — could reprogram adult cells back into a pluripotent state, essentially turning them into stem cells. These induced pluripotent stem cells (iPSCs) were not just functionally young; their epigenetic marks had been completely reset.

In 2013, a landmark paper in the journal Cell proposed nine hallmarks of aging — fundamental biological processes that drive the deterioration we associate with getting old. In 2023, the framework was updated to include three additional hallmarks, bringing the total to twelve. Together, these hallmarks provide a roadmap for understanding aging at the molecular level and a guide for developing interventions.

Anti-aging gene therapy faces several major hurdles. AAV manufacturing is expensive and difficult to scale. Immune responses can limit efficacy and prevent repeat dosing. Long-term safety data for constitutive expression of rejuvenation genes does not yet exist in humans. And the regulatory framework for treating "aging" — which is not classified as a disease by most regulatory agencies — remains unclear.

If Blue Zone research provides suggestive clues, the Mediterranean diet offers the closest thing to proof that a dietary pattern can extend life. The Mediterranean diet — rich in olive oil, vegetables, fruits, legumes, whole grains, fish, and nuts, with limited red meat and processed food — has been studied more rigorously than any other dietary approach in the context of chronic disease and mortality.

Several methods exist for measuring telomere length, each with trade-offs. Terminal Restriction Fragment (TRF) analysis was the original method — reliable but requiring large amounts of DNA. Quantitative PCR (qPCR) is faster and cheaper but less precise. Flow-FISH combines fluorescent probes with flow cytometry and is particularly useful for measuring telomeres in specific cell types like lymphocytes.

A senolytic is a drug or compound designed to selectively induce death (apoptosis) in senescent cells — cells that have permanently exited the cell cycle but refuse to die. Instead of undergoing the normal programmed-death pathway, senescent cells secrete a toxic cocktail of inflammatory cytokines, proteases, and growth factors collectively called the senescence-associated secretory phenotype (SASP).

Cellular senescence is a state in which cells permanently exit the cell cycle but remain metabolically active, secreting inflammatory factors known as the senescence-associated secretory phenotype (SASP). These cells accumulate with age and are now widely accepted as drivers of age-related tissue dysfunction. Senolytics are drugs that selectively kill senescent cells, ideally sparing healthy ones.

Today the honest answer is that we don't know whether GDF11 supplementation would help or harm aging humans. The original cardiac rejuvenation finding has been partially supported by some independent groups and contradicted by others. The muscle findings look weaker. The brain neurogenesis data have held up slightly better, possibly because the brain expresses different activin receptor subtypes.

In 2006, Shinya Yamanaka at Kyoto University demonstrated that introducing just four transcription factors — Oct4, Sox2, Klf4, and c-Myc, now known as the Yamanaka factors or OSKM — could reprogram adult cells back to a pluripotent state, effectively erasing their identity and returning them to something resembling an embryonic stem cell. Yamanaka won the Nobel Prize in 2012 for this discovery.

Epigenetic reprogramming represents a fundamentally different approach to aging. Rather than treating individual age-related diseases one at a time, it addresses the root cause: the epigenetic deterioration that drives all of them simultaneously. If partial reprogramming can be made safe and effective in humans, it would not just add years to life but restore youthful function to aged tissues.

The potential of epigenetic reprogramming attracted unprecedented investment in 2022 when Altos Labs launched with $3 billion in funding — the largest initial investment in biotechnology history. Backed by investors including Yuri Milner and reportedly Jeff Bezos, Altos recruited leading scientists including Yamanaka himself, Steve Horvath, Juan Carlos Izpisua Belmonte, and Jennifer Doudna.

As of early 2026, clinical trials of senolytics in humans have produced encouraging but preliminary results. Several Phase 1 and Phase 2 trials have demonstrated that senolytic compounds can be administered safely in short courses, and some have shown reductions in markers of senescent cell burden and inflammation. No large-scale Phase 3 trial has yet delivered definitive efficacy results.

Navitoclax (ABT-263) is a BCL-2 family inhibitor originally developed as a cancer drug. It is one of the most potent senolytics identified, effectively clearing senescent cells by disabling the anti-apoptotic proteins that keep them alive. In preclinical models, navitoclax rejuvenated the hematopoietic system, improved muscle stem cell function, and reduced atherosclerotic plaque burden.

If you track only one aging biomarker, many longevity physicians would tell you to make it hsCRP. C-reactive protein is produced by the liver in response to inflammation anywhere in the body. The high-sensitivity version of the test can detect very low levels of chronic, systemic inflammation — the kind that silently drives atherosclerosis, neurodegeneration, and cancer over decades [2].

The clinical signatures of proteostasis collapse are unmistakable. Alzheimer's disease is amyloid-β and tau aggregation. Parkinson's disease is α-synuclein aggregation. Huntington's disease is polyglutamine-expanded huntingtin. ALS includes TDP-43 and SOD1 aggregates. Type 2 diabetes involves islet amyloid polypeptide deposits. Cataracts are aggregated crystallin proteins in the lens.

In November 2022, the FDA dropped a bombshell on the NMN supplement market. The agency ruled that NMN could no longer be marketed as a dietary supplement because it was being investigated as a new drug by Metro International Biotech, a company co-founded by David Sinclair. Under FDA rules, once a substance is under investigation as a drug, it generally cannot be sold as a supplement.

No pharmaceutical irisin analog has reached clinical trials as of early 2026, though several companies have explored FNDC5-based or irisin-mimetic approaches. The short half-life of the native peptide and the unusual integrin-based receptor system present drug development challenges. Some groups are exploring small molecule irisin receptor agonists and long-acting peptide analogs.

Tissues are in constant flux. Skin turns over in weeks. Gut epithelium turns over in days. Blood cells are replaced continuously. Skeletal muscle remodels in response to use and injury. When the stem cell engine slows, the visible consequences are some of the most recognizable features of aging: thinner skin, slower healing, lower exercise tolerance, immunosenescence, and frailty.

Perhaps the most dramatic result in the field came from a study where researchers achieved a 109% extension in remaining lifespan in aged mice using a carefully tuned partial reprogramming protocol. The mice received cyclic doses of reprogramming factors starting in late life, and the treated animals lived roughly twice as long as untreated controls from the point of intervention.

The clinical story has centered on NASH (non-alcoholic steatohepatitis) and metabolic dysfunction-associated steatohepatitis (MASH), where FGF21's combination of insulin sensitization, lipid lowering, and anti-fibrotic effects is attractive. Several companies have developed long-acting FGF21 analogs to overcome the native hormone's short half-life of roughly one to two hours.

Telomeres are protective caps at the ends of chromosomes, like the plastic tips on shoelaces. Each time a cell divides, its telomeres get a little shorter. When they become critically short, the cell can no longer divide safely and enters a state of senescence or dies. Telomere shortening acts as a biological countdown clock that limits the regenerative capacity of tissues.

Parabiosis research gave longevity science one of its most provocative findings: that aging is partly a systemic signaling problem, and that the blood itself carries the instructions. Whether we rejuvenate by adding, subtracting, or engineering the signals remains the central question — and the answer will likely shape the next decade of clinical longevity therapeutics.

In 2015, Elizabeth Parrish, CEO of BioViva Sciences, made headlines by announcing that she had undergone two experimental gene therapies intended to combat aging: one delivering telomerase (hTERT) to lengthen her telomeres, and another delivering follistatin to counteract muscle loss. The treatments were administered in Colombia, outside the jurisdiction of the FDA.

In the López-Otín 2013 Cell hallmarks paper, altered intercellular communication is one of the integrative hallmarks — the level at which damage from earlier hallmarks turns into organism-wide functional decline. The 2023 update kept it as a primary integrative hallmark and emphasized its bidirectional crosstalk with chronic inflammation and stem cell exhaustion.

Your DNA accumulates damage throughout your life from radiation, reactive oxygen species, replication errors, and environmental toxins. Cells have sophisticated repair machinery, but it is not perfect. Over time, unrepaired mutations build up in both nuclear and mitochondrial DNA. This genomic instability can cause cells to malfunction, die, or become cancerous.

Elizabeth Blackburn, working at the University of California, Berkeley, studied the chromosomes of Tetrahymena, a pond-dwelling ciliate. In the late 1970s and early 1980s, she and her graduate student Carol Greider made a transformative discovery: an enzyme that could add telomeric DNA repeats back onto chromosome ends, counteracting the end replication problem.

Gene therapy was originally developed to treat rare genetic diseases by delivering a functional copy of a broken gene. But a growing number of researchers are asking a bolder question: what if gene therapy could treat aging itself? Not by fixing a single mutation, but by delivering genes that actively rejuvenate cells, clear damage, or restore youthful function.

No single person has done more to popularize NMN than David Sinclair, a professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. Sinclair's laboratory has produced many of the foundational studies on NAD+ and aging, and he has been extraordinarily public about his personal use of NMN supplements.

Sarcopenia — the progressive loss of muscle mass and strength with age — is one of the most debilitating aspects of aging. It increases fall risk, reduces independence, and accelerates overall decline. Follistatin, a naturally occurring protein that inhibits myostatin (a negative regulator of muscle growth), has emerged as a promising gene therapy target.

The breakthrough for aging research came from the realization that reprogramming is not an all-or-nothing switch. If you expose cells to Yamanaka factors for a limited time — days rather than weeks — you can reverse epigenetic aging marks without erasing cell identity. The cell rejuvenates but remains a skin cell, a neuron, or whatever it was before.

The molecular core of autophagy is beautifully orchestrated. When nutrients are plentiful, the kinase mTORC1 is active and it phosphorylates ULK1, keeping autophagy suppressed. The cell is in "growth" mode. When nutrients drop — during fasting, exercise, or caloric restriction — mTORC1 is inhibited, ULK1 is released, and autophagy initiation begins.

The story begins with heterochronic parabiosis — a surgical technique where a young and old mouse are joined so they share a circulatory system. Thomas Rando and Irina Conboy's landmark 2005 Nature paper showed that old tissues exposed to young blood regained regenerative capacity. The obvious question: what factor in young blood was doing the work?

In the López-Otín 2013 framework, stem cell exhaustion is listed as one of the integrative hallmarks — a downstream consequence of damage accumulating in earlier hallmarks (genomic instability, epigenetic alterations, mitochondrial dysfunction) that ultimately undermines tissue homeostasis. The 2023 update kept it as a primary integrative hallmark.

Life Biosciences was founded in 2017 in Boston by David Sinclair and Tristan Edwards, a former Goldman Sachs and Brevan Howard investment professional. The founding thesis was ambitious and unconventional: rather than targeting a single disease of aging, the company would attack aging itself by pursuing multiple biological hallmarks simultaneously.

The longevity research community's reaction to Johnson has been a study in ambivalence. Most serious researchers respect his commitment to self-measurement and his willingness to publish data openly. But many are uncomfortable with the implied message that extreme spending and extreme interventions are necessary for meaningful healthspan extension.

The high-dose intermittent protocol. The most common biohacker approach is derived from the Mayo trials: roughly 20 mg/kg of oral fisetin for two consecutive days, taken once a month or once a quarter. For a 70 kg adult, that is about 1,400 mg per day for two days. Most people take it with a fatty meal or a lipid carrier to improve absorption.

Deep inside your tissues, a growing population of cells has stopped dividing but refuses to die. These senescent cells — sometimes called "zombie cells" — are alive, metabolically active, and profoundly toxic to their neighbors. They accumulate with age, and mounting evidence suggests they are a major driver of age-related disease and decline.

Few topics in science generate as much noise as diet. Every year brings a new bestseller claiming to have cracked the code — eat this superfood, avoid that macronutrient, fast on these days. But behind the noise, serious researchers have spent decades studying a far more fundamental question: can what you eat actually change how long you live?

The explanation for the Hayflick limit lies in how DNA replication works. When a cell copies its DNA before dividing, the enzyme DNA polymerase cannot fully replicate the very end of a linear chromosome. Each replication cycle leaves a small stretch of DNA at the tip uncopied — like a photocopier that always cuts off the last line of a page.

Hormone replacement therapy. Estrogen replacement at menopause has clear benefits for symptoms and bone, with debated long-term cardiovascular and cancer effects depending on timing. Testosterone replacement in hypogonadal men improves quality of life. Both are area-specific signaling restorations rather than general anti-aging therapies.

The age-related decline in NAD+ is well documented. A 2019 study published in Cell Metabolism by Camacho-Pereira and colleagues showed that CD38 expression increases in multiple tissues with age in mice, directly driving NAD+ decline. Blocking CD38 with pharmacological inhibitors restored NAD+ levels and improved mitochondrial function.

In the López-Otín 2013 Cell hallmarks framework, deregulated nutrient sensing is one of the primary hallmarks. It refers to the age-related disruption of pathways that detect nutrient availability and translate that information into growth, metabolism, and cellular maintenance decisions. The 2023 update preserved it as a core hallmark.

The salvage pathway of NAD+ biosynthesis converts dietary and recycled precursors into NAD+ through a handful of enzymatic steps. NR is phosphorylated by NRK1/2 to NMN, and NMN is adenylated by NMNATs to NAD+. In vitro and in rodent studies, oral NR and NMN both raise tissue NAD+ levels. The mechanistic hope is that restored NAD+ will:

Spermidine is a polyamine — a small, positively charged organic molecule made of a carbon chain with multiple amine groups. Polyamines are ancient. Every living cell makes them, and they play essential roles in DNA stabilization, protein synthesis via translation factor hypusination, membrane interactions, and ion channel regulation.

Dasatinib and quercetin (often abbreviated D+Q) is the most studied senolytic combination in humans. Dasatinib is an FDA-approved tyrosine kinase inhibitor used in cancer treatment, while quercetin is a plant flavonoid found in onions, apples, and green tea. Together, they target different anti-apoptotic pathways in senescent cells.

Caloric restriction (CR) means chronically eating fewer calories — typically 20 to 40 percent below ad libitum intake — without malnutrition. Every essential nutrient has to be met; only energy is reduced. This is distinct from starvation, fasting mimicking diets, and most forms of intermittent fasting, though the pathways overlap.

The ideal time to establish baseline biomarkers is in your late 20s or early 30s, before age-related decline becomes significant. However, there is no age at which starting is "too late" — even in your 50s, 60s, or beyond, tracking biomarkers gives you actionable information and allows you to measure the impact of interventions.

In the López-Otín 2013 Cell hallmarks paper, genomic instability is the first primary hallmark — defined as the age-related accumulation of DNA damage and the failure of DNA repair systems to keep pace. The 2023 update kept it as a primary hallmark and emphasized its role as an upstream driver of nearly every other hallmark.

One of the most striking gene therapy approaches to aging uses adeno-associated virus (AAV) vectors to deliver the Yamanaka factors OCT4, SOX2, and KLF4 — the OSK system — directly into living tissues. Unlike the full four-factor OSKM system, OSK omits c-MYC, a potent oncogene, which dramatically improves the safety profile.

Autophagy — literally "self-eating" in Greek — is the evolutionarily conserved process by which cells degrade and recycle their own components. When a protein misfolds, a mitochondrion becomes dysfunctional, or a pathogen invades, autophagy is how the cell disassembles the offending material and reuses the building blocks.

Franceschi et al. 2000 (Annals of the New York Academy of Sciences) defined inflammaging as "a chronic, low-grade, sterile, systemic inflammation that develops with advanced age." It is "sterile" because it occurs without active infection — the immune system is reacting to endogenous damage signals rather than pathogens.

Klotho is a protein whose discovery reads like a parable about aging. Named after the Greek goddess who spins the thread of life, klotho was identified in 1997 when researchers found that mice lacking the gene aged rapidly and died prematurely, while mice overexpressing it lived 20 to 30 percent longer than normal.

Every cell in your body runs on a molecule you have probably never heard of. It is called nicotinamide adenine dinucleotide, or NAD+, and it is involved in hundreds of essential biological processes — from converting food into energy to repairing damaged DNA. Without NAD+, you would be dead in about 30 seconds.

Senolytics are a class of drugs or compounds designed to selectively kill senescent cells — damaged cells that have stopped dividing but refuse to die. The term was coined in 2015 by Mayo Clinic researchers James Kirkland and Tamara Tchkonia, combining the Latin senex (old) with the Greek lytic (destroying).

Want to estimate where you stand? Our Biological Age Calculator can give you a rough estimate based on key biomarkers. While it does not replace clinical-grade epigenetic testing, it provides a useful starting point for understanding whether your biology is aging faster or slower than your chronological age.

Fisetin is a natural flavonoid found in strawberries, apples, persimmons, and other fruits that has shown senolytic activity in laboratory and animal studies. It is one of the most promising natural senolytics, but rigorous human clinical evidence for its senolytic effects is still limited as of early 2026.

The first pharmacological senolytics were identified by James Kirkland's group at the Mayo Clinic in 2015. Using a targeted approach, they reasoned that senescent cells depend on pro-survival pathways to resist apoptosis — the same pathways that keep them alive as zombie cells could be their Achilles' heel.

Johnson's protocol, for all its idiosyncrasies, exists within a genuine scientific revolution. The field of longevity science has undergone a transformation in the past decade, driven in part by advances in gene editing and epigenetic reprogramming that have changed how researchers think about aging itself.

Fisetin (3,3',4',7-tetrahydroxyflavone) is a flavonol, a subclass of flavonoids, found in strawberries (the densest dietary source), apples, persimmons, onions, cucumbers, and grapes. Strawberries carry roughly 160 micrograms per gram, meaning a cup supplies around 25 mg. Most other foods deliver far less.

Mitophagy is the selective autophagy of mitochondria — the cellular process that identifies damaged or dysfunctional mitochondria, tags them, and sends them for lysosomal degradation. Fresh, healthy mitochondria then replace them via biogenesis. Think of it as quality control for the cell's power plants.

Between 2021 and 2024, Life Biosciences consolidated around its most promising asset. Iduna Therapeutics was formally merged into the parent company in September 2021. The other subsidiaries were either wound down, spun off, or deprioritized. The company brought in experienced pharmaceutical leadership:

Senescent cells do not just sit quietly. They secrete a complex mixture of inflammatory cytokines, chemokines, growth factors, and matrix-degrading enzymes collectively known as the senescence-associated secretory phenotype, or SASP. This secretome is not subtle — it actively damages surrounding tissue.

How do researchers know that partial reprogramming actually reverses aging rather than merely masking its effects? The answer lies in epigenetic clocks — mathematical models developed by Steve Horvath and others that estimate biological age based on DNA methylation patterns at specific genomic sites.

The foundational mechanistic paper is Eisenberg et al., Nature Cell Biology, 2009. Madeo's group showed that spermidine extends lifespan in yeast, nematodes, and fruit flies, and that this extension was dependent on functional autophagy machinery. Knock out the ATG genes and the benefit disappeared.

Fisetin, a flavonoid found in strawberries, apples, and onions, emerged as another promising senolytic from screening studies. In mice, high-dose fisetin reduced senescent cell markers, decreased SASP-related inflammation, and extended both median and maximum lifespan when administered late in life.

Unity Biotechnology was founded in 2011 specifically to develop senolytic medicines and became the first company to take senolytics into clinical trials. Their initial focus was UBX0101, an MDM2/p53 interaction inhibitor designed to clear senescent cells in osteoarthritic joints via local injection.

Chronological age is straightforward: it is the amount of time that has passed since you were born. If you were born on March 15, 1985, your chronological age today is a simple calculation. It moves forward at exactly the same rate for every human being on Earth -- one year per year, no exceptions.

About 85 to 90 percent of human cancers reactivate telomerase. This is not a coincidence — it is a requirement. Cancer cells need to divide indefinitely, and they cannot do that if their telomeres keep shortening. By turning telomerase back on, cancer cells achieve a kind of cellular immortality.

Johnson's most headline-grabbing assertion is that Blueprint has reversed his biological age by approximately 18 years. He claims to have the heart of a 37-year-old, the skin of a 28-year-old, and the lung capacity and fitness of someone decades younger -- despite being 49 years old (born 1977).

Biological age is an estimate of how old your body actually is at the cellular and molecular level, based on measurable biomarkers. It reflects the cumulative wear and tear on your DNA, proteins, organs, and metabolic systems -- shaped by genetics, lifestyle, environment, and disease history.

Senescent cells are cells that have permanently stopped dividing in response to damage or stress but remain metabolically active and resist normal cell death. They are often called "zombie cells" because they are neither fully alive (in the sense of contributing to tissue function) nor dead.

Unlike many longevity interventions, GlyNAC is unusual in that the ingredients are cheap, off-patent, and widely available. There is no major pharmaceutical sponsor. The research is driven almost entirely by Sekhar's group at Baylor, with collaborations at other institutions.

Chronological age is simple: the number of years since you were born. Biological age reflects the actual condition of your cells and tissues. Two people born on the same day can be biologically decades apart depending on genetics, lifestyle, environment, and disease history.

Steve Horvath's multi-tissue clock was the first widely validated epigenetic clock. It uses 353 CpG sites and works across multiple tissue types (blood, brain, liver, kidney, etc.). This versatility made it groundbreaking — previous age predictors only worked in one tissue.

Aging is not a single process. It is a collection of interconnected biological changes — rising inflammation, declining hormone levels, accumulating metabolic damage, immune system deterioration, and more. Each of these processes leaves a measurable signature in your blood.

Some of the most innovative senolytic strategies use gene therapy to selectively destroy senescent cells. These approaches exploit the fact that senescent cells express unique promoters — particularly p16INK4a and p21 — that are largely silent in healthy cells.

Senolytics appear to be reasonably well tolerated in the short, intermittent dosing regimens used in clinical trials so far. However, they are not without risks, and long-term safety data in healthy people using them for anti-aging purposes does not yet exist.

You cannot simply swallow a NAD+ pill. The molecule itself is too large and unstable to survive digestion and enter cells efficiently. Instead, researchers have focused on precursors — smaller molecules that cells can absorb and convert into NAD+ internally.

ER-100 is an AAV-delivered gene therapy encoding the OSK transcription factors (OCT4, SOX2, KLF4). It is administered via intravitreal injection — a needle into the eye, the same route used for anti-VEGF therapies that millions of patients already receive.

Senolytics work by targeting the survival mechanisms that senescent cells rely on to avoid apoptosis (programmed cell death). Normal healthy cells do not depend on these same pathways to the same degree, which is what gives senolytics their selectivity.

Chin et al. 2014 (Nature). The foundational study. In C. elegans, AKG supplementation extended lifespan by about 50% through ATP synthase inhibition and TOR pathway suppression. This established AKG as a legitimate aging target in a model organism.

You can buy quercetin and fisetin over the counter as dietary supplements, but the most studied senolytic combination (D+Q) requires a prescription for the dasatinib component. No product is marketed or approved as a "senolytic" by the FDA.

Senescent cells survive because they upregulate pro-survival pathways — particularly the BCL-2 family of anti-apoptotic proteins (BCL-XL, BCL-W, MCL-1) and tyrosine kinase signaling networks. Senolytic drugs exploit this dependency.

As of 2026, the clinical pipeline for anti-aging gene therapy is expanding but still largely preclinical. The most advanced programs are disease-specific therapies that target age-related conditions rather than aging itself.

Blueprint is not a single intervention. It is a comprehensive system built across several categories, each designed to optimize a different aspect of biological function. Here is what the protocol includes, as of early 2026.

In most adult human cells, telomerase is either absent or present at very low levels. This is why our telomeres shorten with age and why our cells have a finite replicative lifespan. But some cell types are exceptions.

Life Biosciences operates in one of the most closely watched — and most generously funded — areas of biotechnology. Several well-capitalized competitors are pursuing similar approaches to epigenetic reprogramming:

Beyond standard blood biomarkers, several advanced tests attempt to estimate your "biological age" — how old your body actually is at the cellular or molecular level, independent of your chronological age.

David Sinclair is a polarizing figure in the scientific community. While his 2020 Nature paper on OSK-mediated vision restoration has been well-received, other aspects of his work have drawn criticism:

Based on the totality of longevity research -- from large epidemiological studies to randomized controlled trials to centenarian genetics -- here are the three highest-impact, zero-cost interventions:

At the ends of every chromosome in your body sit stretches of repetitive DNA called telomeres. They do not code for any protein. They do not carry any instructions. But they are essential for life.

NAD+ is a coenzyme — a helper molecule that enzymes need in order to work. It participates in two broad categories of cellular activity that are critical to understanding why it matters for aging.

Human evidence is still thin. The mouse data is good; the human data is early. Biohackers taking 20 mg/kg monthly are extrapolating from small trials that have not yet produced hard outcome data.

Here is the critical distinction that gets lost in the spectacle of Blueprint: some of what Johnson does has robust scientific backing, and some of it does not. Separating the two is essential.

The technology that defines Life Biosciences today emerged from a landmark 2020 paper in Nature (Lu et al., Nature 588, 124–129) from Sinclair's Harvard lab. The experiment was elegant:

If you are looking at this list of biomarkers and feeling overwhelmed, here is the encouraging news: a handful of lifestyle interventions improve most of these markers simultaneously.

Inflammaging is increasingly viewed as one of the most actionable hallmarks because it sits at a junction where damage from many sources converges into a common harmful output.

There is no single biomarker that captures biological age perfectly. Instead, researchers use several complementary approaches, each measuring a different dimension of aging.

The clearest evidence that DNA damage drives aging comes from progeroid syndromes — rare genetic diseases in which DNA repair is broken and patients age dramatically faster.

Rapamycin binds the intracellular protein FKBP12, and the FKBP12–rapamycin complex then binds mTORC1, inhibiting its kinase activity. The downstream consequences include:

Understanding the difference between chronological and biological age is not just an academic exercise. It has practical implications for how you manage your health:

The mouse data is encouraging, but what matters for people considering NMN or NR supplements is the human evidence. Here is where the picture becomes more nuanced.

Epigenetic clocks solve a fundamental problem in aging research: how do you measure the effect of an anti-aging intervention without waiting decades?

Despite their surface differences, these protocols converge on a small number of nutrient-sensing pathways that are deeply tied to aging biology:

One of the most important concepts in longevity-oriented blood work is the difference between "normal" reference ranges and "optimal" ranges.

Across Blue Zone studies, clinical trials, animal research, and molecular biology, certain dietary principles show up again and again:

Focus: Partial reprogramming, autophagy, plasma-inspired therapies Founded: 2021 | Funding: $180 million (initial), led by Sam Altman

Clocks matter for gene editing and peptide therapeutics because they are how we'll measure whether rejuvenation actually worked.

Not all longevity researchers share Sinclair's enthusiasm for NAD+ supplementation. The criticism falls into several categories:

Epigenetic clocks are mathematical models that estimate biological age by measuring DNA methylation patterns across the genome.

Life Biosciences initially operated as a holding company with six subsidiaries, each targeting a different hallmark of aging:

Research using epigenetic clocks and other biomarkers has identified several factors that reliably speed up biological aging:

The mechanism of metformin is still, after six decades, only partially understood. The best-supported model involves:

This is where the science gets genuinely exciting. Unlike chronological age, biological age responds to intervention.

Several claims from the blue zones literature have genuine scientific support independent of the centenarian counts.

Life Biosciences has raised approximately $150–175 million across seven rounds from 14–16 investors. Notable rounds:

VO2 max correlates with mortality through several mechanisms that overlap with established hallmarks of aging:

Chronically high mTOR signaling, low AMPK, and low sirtuin activity together produce a cellular state that:

Focus: AI-driven drug discovery for aging and age-related diseases Founded: 2014 | Funding: $400+ million

Glutathione is often described as the body's master antioxidant, but the label undersells its role. GSH:

GlyNAC is not a branded drug. It is a supplement regimen combining two widely available amino acids:

Klotho does not fit neatly into one pathway. Its biology is spread across several organ systems.

Focus: Epigenetic reprogramming and cellular rejuvenation Founded: 2022 | Funding: $3+ billion

Focus: Epigenetic reprogramming for specific cell types Founded: 2022 | Funding: $40+ million

Despite the excitement, the field faces substantial scientific and translational challenges.

Clocks are useful only if they respond to interventions. Here's where they've been tested:

Focus: Senolytic medicines for age-related diseases Founded: 2011 | Publicly traded: UBX

Focus: Understanding the biology of aging Founded: 2013 | Backed by: Alphabet (Google)

When intercellular signaling becomes noisy, three things happen at the system level:

Several commercial services now offer biological age testing directly to consumers:

Several strategies for addressing telomere-related aging are under investigation.

Focus: mRNA-based epigenetic reprogramming Founded: 2018 | Funding: $60+ million

Yes -- and there is growing evidence from human studies, not just animal models.

The proposed mechanisms are multifactorial and still being disentangled:

Let's separate mouse data (compelling) from human data (preliminary).

Despite decades of work, several big questions remain unresolved:

The exciting part — interventions that slow the epigenetic clock:

The mechanistic case for AKG in longevity rests on four pillars:

First-generation clocks (chronological-age predictors).

The epigenetic clock ecosystem in 2026 includes:

Photo by National Cancer Institute on Unsplash

Then Novartis tried to replicate the work.

Photo by Mariana Medvedeva on Unsplash

Photo by Michael Schiffer on Unsplash